2016_Head & Neck COURSE BOOK

EGFR/HER3 or pan-HER inhibition

Study

N Regimens

ORR Median PFS MEHD7945A 14.5% 11.9% 4 months 4.1 months 8.5 months 7.2 months 5.6% 10.2% 1.7 months 2.6 months* 6 months 6.8 months Median Survival

Fayette ESMO LBA 2014 62 59 Cetuximab versus Machiels** Lancet Oncol 2015 161 322 Methotrexate versus Afatinib

* Statistically significant ** Previous used of cetuximab allowed